# Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer

> **NCT01387880** · PHASE2 · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 100 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01387880
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-11
- **Final completion:** 2012-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2012-03-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01387880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01387880, "Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01387880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*